Nature Communications (Jul 2021)
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
- Cesheng Li,
- Ding Yu,
- Xiao Wu,
- Hong Liang,
- Zhijun Zhou,
- Yong Xie,
- Taojing Li,
- Junzheng Wu,
- Fengping Lu,
- Lu Feng,
- Min Mao,
- Lianzhen Lin,
- Huanhuan Guo,
- Shenglan Yue,
- Feifei Wang,
- Yan Peng,
- Yong Hu,
- Zejun Wang,
- Jianhong Yu,
- Yong Zhang,
- Jia Lu,
- Haoran Ning,
- Huichuan Yang,
- Daoxing Fu,
- Yanlin He,
- Dongbo Zhou,
- Tao Du,
- Kai Duan,
- Demei Dong,
- Kun Deng,
- Xia Zou,
- Ya Zhang,
- Rong Zhou,
- Yang Gao,
- Xinxin Zhang,
- Xiaoming Yang
Affiliations
- Cesheng Li
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Ding Yu
- Chengdu Rongsheng Pharmaceuticals Co., Ltd
- Xiao Wu
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Hong Liang
- Chengdu Rongsheng Pharmaceuticals Co., Ltd
- Zhijun Zhou
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Yong Xie
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Taojing Li
- Beijing Tiantan Biological Products Co., Ltd
- Junzheng Wu
- Chengdu Rongsheng Pharmaceuticals Co., Ltd
- Fengping Lu
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Lu Feng
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Min Mao
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Lianzhen Lin
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Huanhuan Guo
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Shenglan Yue
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Feifei Wang
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Yan Peng
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Yong Hu
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Zejun Wang
- Wuhan Institute of Biological Products Co. Ltd
- Jianhong Yu
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Yong Zhang
- Beijing Tiantan Biological Products Co., Ltd
- Jia Lu
- Wuhan Institute of Biological Products Co. Ltd
- Haoran Ning
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Huichuan Yang
- China National Biotec Group Company Limited
- Daoxing Fu
- Beijing Tiantan Biological Products Co., Ltd
- Yanlin He
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Dongbo Zhou
- Beijing Tiantan Biological Products Co., Ltd
- Tao Du
- Beijing Tiantan Biological Products Co., Ltd
- Kai Duan
- Wuhan Institute of Biological Products Co. Ltd
- Demei Dong
- Beijing Tiantan Biological Products Co., Ltd
- Kun Deng
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Xia Zou
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Ya Zhang
- Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
- Rong Zhou
- Beijing Tiantan Biological Products Co., Ltd
- Yang Gao
- Beijing Tiantan Biological Products Co., Ltd
- Xinxin Zhang
- Research Laboratory of Clinical Virology, Ruijin Hospital and Ruijin Hospital North, National Research Center for Translational Medicine, Shanghai Jiao Tong University of Medicine
- Xiaoming Yang
- China National Biotec Group Company Limited
- DOI
- https://doi.org/10.1038/s41467-021-24230-5
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 9
Abstract
COVID-19 pandemic is a global health risk, but our understanding on the induced durable immunity remains scarce. Here the authors assess antibody responses in 869 convalescent COVID-19 patients to find that specific antibody titers reduce with time, and the RBD-IgG positive rate exceed 70% at 12 month post diagnosis, with male and older patients showing stronger responses.